Sekido N, Miyanaga N, Kikuchi K, Takeshima H, Akaza H
Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
Jpn J Clin Oncol. 1999 Oct;29(10):479-84. doi: 10.1093/jjco/29.10.479.
Intra-arterial chemotherapy with concurrent pelvic radiotherapy as a bladder-sparing regimen for invasive bladder cancer is highly promising for selected patients. However, lower urinary tract function after this treatment has not been fully investigated.
The urodynamic effects of intra-arterial chemotherapy with concurrent pelvic radiotherapy were retrospectively evaluated in 14 patients with organ-confined invasive bladder cancer. The post-treatment urodynamic findings were compared with the pretreatment ones (n = 7), and a comparison was made between the serial urodynamic findings after the treatment in another seven patients who were able to undergo the pretreatment urodynamic study (UDS).
The median follow-up period up to the latest UDS was 34 months. Of the 14 patients, the latest UDS revealed some storage dysfunctions in 11 (79%) and some emptying dysfunctions in three (23%). Uninhibited detrusor contraction and decreased bladder compliance were recorded in 29 and 43% at the pretreatment UDS and approximately 50-60 and 20-60% in the serial follow-up studies, respectively (n = 7). Impaired detrusor contractility lasted in one patient. In the seven patients without the pretreatment UDS, decreased maximum cystometric capacity and decreased compliance were recorded in approximately 50-60 and 20-60% at the serial UDS, respectively. Detrusor contractility was aggravated in one patient and completely lost in one with time.
The urodynamic findings indicate that the bladder-sparing regimen might result in perpetuating the lower urinary tract dysfunctions due to invasive bladder cancer itself and/or transurethral surgery and might injure the infrasacral autonomic nerves and the bladder itself.
对于部分选定的患者,动脉内化疗联合盆腔放疗作为浸润性膀胱癌的保膀胱方案极具前景。然而,这种治疗后的下尿路功能尚未得到充分研究。
回顾性评估了14例器官局限性浸润性膀胱癌患者接受动脉内化疗联合盆腔放疗后的尿动力学效应。将治疗后的尿动力学结果与治疗前的结果(n = 7)进行比较,并对另外7例能够进行治疗前尿动力学研究(UDS)的患者治疗后的系列尿动力学结果进行比较。
截至最新一次UDS的中位随访期为34个月。14例患者中,最新一次UDS显示11例(79%)存在一些储尿功能障碍,3例(23%)存在一些排尿功能障碍。在治疗前的UDS中,分别有29%和43%记录到逼尿肌无抑制性收缩和膀胱顺应性下降,在系列随访研究中分别约为50 - 60%和20 - 60%(n = 7)。1例患者持续存在逼尿肌收缩力受损。在7例未进行治疗前UDS的患者中,系列UDS显示分别约有50 - 60%和20 - 60%的患者最大膀胱测压容量下降和顺应性下降。1例患者逼尿肌收缩力随时间加重,1例完全丧失。
尿动力学结果表明,保膀胱方案可能会因浸润性膀胱癌本身和/或经尿道手术导致下尿路功能障碍持续存在,并可能损伤骶神经自主神经和膀胱本身。